Haben Sie sich noch nicht registriert? Hier kostenlos Ihr Konto eröffnen.
Passwort vergessen? Wir werden Ihnen einen Zurücksetzen Link senden
1 Mai 2024
TRYP THERAPEUTICS AND EXOPHARM LIMITED ANNOUNCE COMPLETION OF PLAN OF ARRANGEMENT
24 April 2024
TRYP THERAPEUTICS PROVIDES UPDATE ON PLAN OF ARRANGEMENT WITH EXOPHARM LIMITED AND ANNOUNCES VOLUNTARY TRADING HALT
12 März 2024
TRYP THERAPEUTICS ANNOUNCES 99.92% VOTES CAST BY SHAREHOLDERS IN FAVOR OF ARRANGEMENT AGREEMENT AT ANNUAL GENERAL AND SPECIAL MEETING OF SECURITYHOLDERS, AND RECEIPT OF FINAL ORDER
8 Februar 2024
TRYP THERAPEUTICS OBTAINS INTERIM ORDER FOR PLAN OF ARRANGEMENT AND PROVIDES DETAILS OF SHAREHOLDER MEETING
26 Januar 2024
TRYP THERAPEUTICS AND EXOPHARM LIMITED SECURE PIVOTAL 2 CENT WAIVER FROM ASX
8 Januar 2024
TRYP THERAPEUTICS ANNOUNCES SIGNIFICANT MILESTONE IN ITS CLINICAL TRIAL PROGRAM FOR TRP-8803 (IV-INFUSED PSILOCIN)
4 Januar 2024
TRYP THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2a CLINICAL TRIAL FOR THE TREATMENT OF FIBROMYALGIA AT THE UNIVERSITY OF MICHIGAN
11 Dezember 2023
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
20 November 2023
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
3 August 2023
TRYP THERAPEUTICS ANNOUNCES JASON CARROLL AS NEW CHIEF EXECUTIVE OFFICER
2 August 2023
WITH GREAT SADNESS TRYP ANNOUNCES THE PASSING OF DAVID TOUSLEY, DIRECTOR
13 Juli 2023
TRYP THERAPEUTICS RECEIVES CONFIRMATION FROM FDA TO PROCEED WITH PHASE 2A CLINICAL TRIAL IN PATIENTS WITH IBS AT MASSACHUSETTS GENERAL HOSPITAL
24 Mai 2023
TRYP THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO US FDA FOR PLANNED PHASE 2a CLINICAL TRIAL IN PATIENTS WITH IBS AT MASSACHUSETTS GENERAL HOSPITAL
27 April 2023
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Secured Convertible Debentures for Gross Proceeds of AUD$2,400,000
12 April 2023
Tryp Therapeutics Announces Private Placement of Secured Convertible Debentures for Gross Proceeds of a minimum of AUD$2,000,000
4 April 2023
TRYP THERAPEUTICS COMPLETES PSYCHOTHERAPY TRAINING FOR PLANNED PHASE 2a CLINICAL TRIAL AT MASSACHUSETTS GENERAL HOSPITAL